Patents by Inventor Joseph B Santella, III

Joseph B Santella, III has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterocycyclic piperidines as modulators of chemokine receptor activity
    Patent number: 6331545
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: December 18, 2001
    Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Dean A. Wacker
  • N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
    Patent number: 6331541
    Abstract: The present application describes modulators of CCR3 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: December 18, 2001
    Inventors: Soo S. Ko, George V. DeLucca, John V. Duncia, Joseph B. Santella, III, Daniel S. Gardner
  • N-adamant-1-y1-N1-[4-chlorobenzothiazol-2-y1] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
    Patent number: 6214851
    Abstract: This invention relates generally to N-adamant-1-yl-N′-[4-chlorobenzothiazol-2-yl] urea, pharmaceutical compositions comprising the same, and methods of using the same in the treatment of inflammation and as an anticancer radiosensitizing agent.
    Type: Grant
    Filed: March 17, 2000
    Date of Patent: April 10, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: John J. V. Duncia, Daniel S. Gardner, IV, Joseph B Santella, III
  • Boronic acid and ester inhibitors of thrombin
    Patent number: 5563127
    Abstract: Novel boronic acid and ester and carboxyl-modified amino acid compounds of the Formula I, which are inhibitors of trypsin-like enzymes, are disclosed :R.sup.1 --Z--CHR.sup.2 --A,where R.sup.1, Z, R.sup.2 and A are defined within.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: October 8, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: Eugene C. Amparo, William H. Miller, Gregory J. Pacofsky, John Wityak, Patricia C. Weber, John J. V. Duncia, Joseph B. Santella, III
  • Imidazole 5-position substituted angiotensin II antagonists
    Patent number: 5545651
    Abstract: Novel substituted imidazoles of Formula (I), which are useful as angiotensin II antagonists, are disclosed: ##STR1##
    Type: Grant
    Filed: November 28, 1994
    Date of Patent: August 13, 1996
    Assignee: The DuPont Merck Pharmaceutical Company
    Inventors: John J. V. Duncia, Carol L. Ensinger, Richard E. Olson, Mimi L. Quan, Joseph B. Santella, III, Mary K. Vanatten
  • Imidazole 5-position substituted angiotensin II antagonists
    Patent number: 5395844
    Abstract: Novel substituted imidazoles of Formula (III), which are useful as angiotensin-II antagonists, are disclosed: ##STR1## These compounds, exemplified by the compound 1-((2'-((i-Amyloxycarbonylamino)sulfonyl)-3-fluoro-(1,1'-biphenyl)-4-yl)me thyl)-5-[2-(N-butyryl-N-pyridin-3-ylamino) ethylcarbonyl]-4-ethyl-2-propyl-1H-imidazole, are useful as antihypertensive agents.
    Type: Grant
    Filed: June 10, 1993
    Date of Patent: March 7, 1995
    Assignee: The Du Pont Merck Pharmaceutical Company
    Inventors: John J. V. Duncia, Carol L. Ensinger, Richard E. Olson, Mimi L. Quan, Joseph B. Santella, III, Mary K. Vanatten